A study published today in Muscle & Nerve on the long-term data from the CENTAUR clinical trial and open-label extension shows that AMX0035 has promise for extending survival in people living with ALS.
The results demonstrated that early treatment with AMX0035 resulted in longer survival for people living with ALS on the therapy during the Phase 2 clinical trial compared to those who only received it during the open-label extension. The study, sponsored by the pharmaceutical company Amylyx, followed participants for up to three years from the CENTAUR trial. This data complements the study published in September 2020 in the New England Journal of Medicine, which demonstrated AMX0035 was safe and slowed the rate of decline in people living with ALS compared to those on placebo.
ALS Canada continues to actively engage with Amylyx to advocate for the company to include Canada in their future plans.
You can read more about the results here.